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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.009Because there is clinical evidence for an association between periodontal disease and rheumatoid
arthritis, it is important to develop suitable experimental models to explore pathogenic mechanisms and
therapeutic opportunities. The K/BxN serum model of inﬂammatory arthritis was applied using distinct
protocols, and modulation of joint disruption afforded by dexamethasone and calcitonin was established
in comparison to the melanocortin (MC) receptor agonist DTrp8eg-melanocyte stimulating hormone
(MSH; DTrp). Wild-type and MC receptor type 3 (MC3)-null mice of different ages were also used. There
was signiﬁcant association between severity of joint disease, induced with distinct protocols and vol-
umes of the arthritogenic K/BxN serum, and periodontal bone damage. Therapeutic treatment with 10 mg
dexamethasone, 30 ng elcatonin, and 20 mg DTrp per mouse revealed unique and distinctive pharma-
cological properties, with only DTrp protecting both joint and periodontal tissue. Further analyses in
nonarthritic animals revealed higher susceptibility to periodontal bone loss in Mc3r/ compared with
wild-type mice, with signiﬁcant exacerbation at 14 weeks of age. These data reveal novel protective
properties of endogenous MC3 on periodontal status in health and disease and indicate that MC3 acti-
vation could lead to the development of a new genus of anti-arthritic bone-sparing therapeutics.
(Am J Pathol 2014, 184: 2333e2341; http://dx.doi.org/10.1016/j.ajpath.2014.04.009)Supported by Medical Research Council grant MR/K013068/1 (M.P. and
T.M.M.), William Harvey Research Foundation (M.P. and L.V.N.), and Con-
selho Nacional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq
M.F.M.M., T.A.dS.; Brazil).
Disclosures: None declared.Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
associated with progressive disability, early death, increased
risk of cardiovascular events, and other extra-articular
manifestations that have a major impact in the quality of
life of those with the disease.1,2 The current clinical
approach is to start early, after diagnosis, with aggressive
therapy, followed by treatment adjustments according to
changes in disease activity. However, despite the important
progress in RA therapies during the past decade, several
needs are still unmet. The introduction of biological agents
in the early 1990s revolutionized the treatment of RA and
other chronic diseases, such as inﬂammatory bowel disease.
However, although highly effective and generally faster
acting than disease-modifying anti-rheumatic drugs, many
patients are not responsive, and they may also experience anstigative Pathology.
.increased risk of opportunistic infections. The treatments are
costly.3 Thus, there is justiﬁcation for exploiting novel
therapies. In addition, it is also desirable to produce new
therapeutics with efﬁcacy on pain and inﬂammation in the
joint, but also able to temper systemic complications of RA
affecting the heart, lungs, muscles, and bone.1
Targeting the melanocortin (MC) system4 to treat RA
may represent an alternative opportunity to drug discovery.5
Indeed, one of the melanocortin agonists, adrenocortico-
tropin hormone (ACTH), was shown to be effective in
Montero-Melendez et alhuman RA >60 years ago6; researchers are showing a
renewed interest.7 This is prompted by the fact that ACTH
may afford biological actions beyond the endogenous pro-
duction of cortisol,8,9 provoking activation of peripheral MC
receptors, including the melanocortin receptor 3 (MC3).
This peripheral mechanism of action of ACTH, hence in-
dependent from adrenal release of glucocorticoids, might
also underlie efﬁcacy in conditions such as proteinuric ne-
phropathies10 and multiple sclerosis.11
Surmounting evidence indicates an important counter-
regulatory role for the melanocortin pathway during inﬂam-
mation, including in the osteo-articular system, where
melanocortin receptors are expressed by osteoblasts, osteo-
clasts, chondrocytes, ﬁbroblasts, and immune cells. Pharma-
cological targeting with MC peptides leads to a variety of
protective actions, including increased matrix deposition,
reduced ﬁbroblast activation, and osteoblast and chondrocyte
proliferation.12e17 In vivo, the synthetic peptide DTrp8eg-
melanocyte stimulating hormone (MSH; DTrp) reduces clin-
ical signs of disease in models of inﬂammatory arthritis18 and
urate crystal peritonitis19 by a mechanism involving MC3. In
addition, the pan-MC agonist peptide AP214 also displays
anti-arthritic properties.20 Recent work by Gomez-SanMiguel
et al21 reported that the MC agonist aMSH can reduce joint
inﬂammation, together with an improvement of extra-articular
signs associated with systemic arthritis, by increasing body
weight and reducing levels of muscle-wasting markers.
An important clinical manifestation associated with arthritis
is periodontal disease. There is epidemiological evidence
associating inﬂammation of the gum with incidence of RA22
and, conversely, there is a higher incidence of periodontitis
in RA patients.23 Intriguingly, recent reports demonstrated the
presence of alveolar bone loss, an important feature of peri-
odontitis, in rodents during the time course of experimental
models of arthritis, namely collagen- and adjuvant-induced
arthritis.24e26 Herein, we investigated the presence of alve-
olar bone loss in a different model of experimental arthritis:
one induced by the arthritogenic K/BxN serum, which is much
faster in its kinetics, and is characterized by leukocyte inﬁl-
tration, synoviocyte proliferation, and cartilage and bone
erosion, thus resembling many features of human RA in its
active ﬂares.27,28 In addition, we established the involvement
of the melanocortin system in the development of alveolar
bone loss by using a combination of genetically engineered
mice and pharmacological approaches.
Materials and Methods
Animals
The 7- to 8-week-oldmalemiceweremaintained on a standard
chow pellet diet and had free access to water with a 12-hour
light-dark cycle. C57BL/6J wild-type (WT) mice were pur-
chased from Charles River (Kent, UK).Mc3r/ mice were a
generous gift of Dr. Howard Chen (Merck Laboratories,
Rahway, NJ). All animal studies were approved and2334performed under the guidelines of the Ethical Committee for
the Use of Animals, Barts and The London School of Medi-
cine (London, UK), and Home Ofﬁce Regulations (Guidance
on the Operation of Animals, Scientiﬁc Procedures Act, 1986).
Production of K/BxN Serum
K/BxN mice were produced by crossing the C57BL/6 mice
(carrying the KRN homozygously) and the NOD/Lt mice (car-
rying the Ag7 allele homozygously).27 The offspring develop
spontaneous arthritis, evident at 6 weeks, with 100% incidence.
At 9 weeks of age (when the titers of antieglucose-6-phosphate
isomerase antibodies aremaximal, implyingpotent arthritogenic
properties of the serum), mice were exsanguinated by cardiac
puncture under anesthesia (isoﬂurane). Blood was allowed to
clot overnight at 4C. Serum was recovered with a Pasteur
pipette and centrifuged 10minutes at 500 g at 4C. The serum
fromdifferentmice obtained on a given daywas pooled, divided
into aliquots, and stored at80C until use.
K/BxN Serum Transfer Arthritis Model
Arthritis was induced by the i.p. injection of serum from K/
BxN arthritic mice. Three different protocols were studied: i)
protocol 50þ 50, where mice received two injections of 50 mL
of serum on days 0 and 2; ii) protocol 100þ 100, where mice
received two injections of 100 mL of serum on days 0 and 2;
and iii) protocol 200, consisting of one single injection of 200
mL of serum on day 0. The protocol 100 þ 100 was then
selected for subsequent experiments. The development of the
disease was monitored daily by assessing the paw volume
using a plethysmometer (Ugo Basile, Comerio, Italy), body
weight, clinical score (score per paw: 0, no signs of inﬂam-
mation; 1, subtle inﬂammation, localized; 2, easily identiﬁed
inﬂammation, but localized; 3, evident inﬂammation, not
localized; maximum score Z 12 per mouse), and disease
incidence [mice showing overt signs of joint inﬂammation (ie,
a clinical score of1)].29 Severe arthritis (number of paws per
mouse that reached a maximum score of 3) was also recorded.
Pharmacological Treatments
Mice (nZ 5) were treated i.p. once daily, starting from day
2 (1 hour after the second K/BxN injection), with 10 mg per
mouse dexamethasone (Dex; Sigma, Poole, UK), 20 mg/
mouse DTrp (American Peptide, Sunnyvale, CA), 30 ng per
mouse elcatonin (ECT; Bachem, Bubendorf, Switzerland),
or vehicle (PBS). Doses were selected from previous studies
in this or similar rodent models.18,30,31
Measurement of Alveolar Bone Loss
Alveolar bone loss was evaluated as previously described.32
Mice were euthanized and maxillae were hemisected,
exposed overnight in 3% hydrogen peroxide, mechanically
deﬂeshed, and stained with 0.3% methylene blue. Images ofajp.amjpathol.org - The American Journal of Pathology
MC3 Controls Bone Lossthe palatal faces of the molars were obtained using a ste-
reomicroscope and a digital camera (Kodak EasyShare
C743; Rochester, NY). Quantitative analyses included the
measurement of the area between the cement enamel junc-
tion and the alveolar bone crest in the ﬁrst molar, using
ImageJ software version 1.46e (NIH, Bethesda, MD).
Activity Assay
Myeloperoxidase (MPO) activity was measured as an index of
granulocyte inﬁltration. Brieﬂy, maxillae tissue samples were
homogenized in 0.5% hexadecyltrimethylammonium bromide
dissolved in phosphate buffer solution (pH 6) using a Pre-
cellys24 homogenizer in Precellys lysing CK14 tubes (Bertin
Technologies; distributed by VWR International, Dublin,
Ireland). The homogenized tissues were centrifuged at
13,000  g for 5 minutes (at 4C), and the supernatants were
placed on 96-well plates. Buffer, supplemented with 1%
hydrogen peroxide/O-dianisidine dihydrocholoride, was
added to each well. Optical density readings were taken for 3
minutes at 30-second intervals at 450 nm using a microplate
reader NOVOstar (BMG Labtech, Aylesbury, UK). Activity
was normalized to the sample protein concentration deter-
mined with a bicinchoninic acid kit (Pierce, Cramlington,
UK), and MPO activity is expressed as U/mL of homogenated
samples.
Histological Analysis
Maxillae tissues were ﬁxed in 10% buffered formalin (pH 7.4)
for 24 hours at room temperature. The specimens were dem-
ineralized in 14% EDTA for 2 weeks, dehydrated in graded
ethanol, and embedded in parafﬁn. Serial sections (5 mm thick)
were stained for tartrate-resistant acid phosphatase (TRAP;
Sigma-Aldrich, St. Louis, MO). Histological osteoclast
counting was performed in the coronal two thirds of the distal
alveolar bone adjacent to the ﬁrst molar in ﬁve consecutive
microscopic ﬁelds (40 magniﬁcation per section). Samples
were analyzed using an Axioskop 40 microscope (Carl Zeiss,
Gottingen, Germany), attached to a digital camera (PowerShot
A620; Canon, Tokyo, Japan). For each animal (nZ 4), three
maxillae sections were analyzed. All of the slides were counted
in a blinded manner by a single examiner (M.F.M.M.). For
neutrophil staining, tissue specimens were blocked by incu-
bation in 1.5% H2O2 in methanol solution for 30 minutes.
Primary antibody against neutrophil elastase (Santa Cruz
Biotechnology, Heidelberg, Germany) was used with a Vec-
tastain avidin-biotin complex kit anti-rabbit (Vector Labora-
tories, Burlingame, CA). The sections were counterstained
using hematoxylin. Slides were developed using a peroxidase
substrate diaminobenzidine kit (Vector Laboratories).
Statistical Analysis
Datawere analyzedbyStudent’s t-test, one- or two-way analysis
of variance, followed by Bonferroni or multiple-comparisonThe American Journal of Pathology - ajp.amjpathol.orgtest, or two-way analysis of variance, followed by Newman-
Keuls multiple-comparison test or Pearson correlation test, as
appropriate. In all cases, data are presented as means SEM of
n independent observations and were considered statistically
signiﬁcant when P < 0.05.
Results
Arthritis Severity in the K/BxN Serum Transfer Model
Correlates with Alveolar Bone Loss
Recent reports have indicated that experimental models of
collagen- and antigen-induced arthritis are associated with
development of alveolar bone loss. We evaluated whether
development of aggressive joint inﬂammation using the K/
BxN serum transfer model of arthritis was also associated
with this extra-articular manifestation. We, therefore, used
three dosing strategies to manipulate the severity of arthritis:
mice received two injections of either 50 or 100 mL of serum
on days 0 and 2 (protocol 50 þ 50 or protocol 100 þ 100,
respectively) or a single injection of 200 mL of serum on day
0 (protocol 200). All three regimens induced overt signs of
arthritis. As expected, the arthritic response produced with
protocol 50 þ 50 was milder, evidenced by the low clinical
score (Figure 1A), transient increase in paw volume
(Figure 1B), and reduced severity (Figure 1C) compared
with the other two protocols. Comparatively, although mice
received the same total amount of arthritogenic serum using
protocols 100 þ 100 and 200, administration in two separate
injections (days 0 and 2) resulted in higher clinical scores,
more gradual and consistent increase in paw volume, and,
more important, 100% disease incidence (Figure 1D). We
next analyzed alveolar bone loss in the maxillae of these
mice subjected to serum transfer-induced arthritis. Interest-
ingly, bone loss in the maxillae was highly correlated with
the severity of localized inﬂammation in the joints
(Figure 2A), suggesting that extra-articular manifestations
of relevance for RA also occur in this model. An overall
comparison between nonarthritic and arthritic mice indi-
cated a signiﬁcant (21%) increase in alveolar bone loss
(Figure 2B). This could also be seen macroscopically by an
increased corono-apical area between the cement-enamel
junction and the alveolar bone crest on the palatal side of
the ﬁrst molar (Figure 2C).
Melanocortin Treatment Reduces Arthritis and Prevents
Alveolar Bone Loss
The melanocortin system is widely associated with joint
disease and inﬂammation both mechanistically and thera-
peutically.5,8,18,19 We studied if pharmacological interven-
tion with melanocortin-based compounds could have an
impact, not only in joint inﬂammation or other arthritis-
related manifestations, such as cachexia, as recently
described,21 but also in alveolar bone loss. We, therefore,
assessed whether the peptide DTrp could prevent the2335
Figure 1 Comparison of three protocols for the K/BxN serum transfer
arthritis model. Arthritis was induced by the i.p. injection of serum from K/
BxN arthritic mice using three different protocols: 50 þ 50 (two injections
of 50 mL on days 0 and 2); 100 þ 100 (two injections of 100 mL on days
0 and 2); and 200 (one single injection on day 0). Clinical score (A), paw
volume (B), and disease incidence (C) were recorded for 7 days. D: The
number of paws per mouse that reached the maximum score (3). E:
Representative images of ankle, wrist, and digit swelling. Data are the
means  SEM of four to six mice per group. *P < 0.05, two-way analysis of
variance, followed by Bonferroni multiple-comparison test. Ctrl, control.
Montero-Melendez et aldevelopment of alveolar bone loss we observed using this
passive transfer model of arthritis. Dex, potent as an anti-
inﬂammatory drug but with detrimental bone effects, and
ECT, a bone-protective molecule but with mild anti-
inﬂammatory effects, were used for comparison. As ex-
pected, Dex afforded a potent anti-inﬂammatory effect,
reducing clinical score (40% at day 8) (Figure 3A), paw
volume (59%) (Figure 3B), and incidence of severe
arthritis (93%) (Figure 3C). The effect of ECT was less
pronounced, with a signiﬁcant statistical difference only in
reducing paw volume. DTrp presented a moderate and
signiﬁcant attenuation in all parameters measured (clinical
score, 23%; paw volume, 44%; severity, 57%).
Determination of MPO activity in maxillae tissues
(analyzed at day 8) showed a signiﬁcant reduction in the
groups treated with either Dex or DTrp, but not with ECT
(Figure 3E). Although the degree of anti-inﬂammatory ac-
tivity attained by treatment of animals with Dex and DTrp in
the periodontal tissue appears to be similar, assessment
of alveolar bone loss revealed interesting differences: the2336anti-arthritic effect of DTrp is associated with bone protec-
tion, as evident from the positive correlation (r Z 0.87) be-
tween bone loss and clinical score (Figure 3F). In contrast,
the anti-arthritic effect of Dex was inversely correlated with
alveolar bone loss (rZ 0.87), in accordance with the well-
known effects of Dex on bone metabolism. These ﬁndings
suggest that melanocortin therapy, in addition to potent
modulation of inﬂammation and arthritis, could also have the
advantage over corticoid therapy in preserving bone integrity.
MC3-Deﬁcient Mice Display Increased Alveolar Bone
Loss
Our next approach consisted of the study of the role of MC3
using genetically modiﬁed mice lacking this receptor,
because it has been reported that MC3 is a pivotal target for
the anti-inﬂammatory and anti-arthritic actions of melano-
cortin drugs, including ACTH.8,9 Arthritis was induced
using the 100 þ 100 protocol, as in previous experiments,
although in this case, 12-week-old mice were used (because
of stock availability). As shown in Figure 4, arthritis
developed similarly to previous experiments with younger
mice. The clinical score and disease severity were identical
in WT and Mc3r/ mice, although some differences were
found in the paw volume (Figure 4). As expected, when
alveolar bone loss was assessed in maxillae (day 8), WT
arthritic mice presented an increase in bone loss, corrobo-
rating our previous ﬁndings. However, the basal values of
alveolar bone loss obtained in Mc3r/ mice were elevated
compared with WT mice, and no further alveolar bone loss
was obtained after arthritis induction (Figure 4D). The fact
that the mice used in this experiment were older made us
hypothesize that there might be an association between MC3
deﬁciency and physiological bone metabolism.
Aging-Associated Alveolar Bone Loss Is Accelerated in
MC3-Deﬁcient Mice
The evidence obtained in our previous experiments suggests
that activation of MC3 (the main receptor that mediates
DTrp actions19) might protect from alveolar bone loss.
Because there is evidence in the literature furthering an
association between the melanocortin system and bone
metabolism,12 as well as linking normal bone loss associ-
ated with aging,33,34 next we sought to investigate if MC3
played any role in these phenomena.
Maxillae from WT and Mc3r/ mice, harvested at
different ages (1.5, 3.5, and 4.5 months old), were analyzed
for alveolar bone loss. Interestingly, periodontal bone loss
was accelerated in Mc3r/ mice, showing a 39% increase
at 3.5 months of age compared with younger mice (1.5
months), whereas only a 15% increase was observed in
same-age WT mice (Figure 5).
There is some indication for a functional association be-
tween MC3 and osteoclastogenesis, because the number of
osteoclasts is increased in Mc3r/ arthritic mice, comparedajp.amjpathol.org - The American Journal of Pathology
Figure 2 Correlation of arthritis with alveolar bone loss in the K/BxN serum transfer model. Alveolar bone loss was evaluated at day 7 in the palatal aspect
of the ﬁrst upper molar of the right hemimaxillae. A: Correlation between alveolar bone loss and clinical score on mice studied in the protocol comparison
experiment (Figure 1) analyzed by Pearson correlation test (n Z 14). B: Overall increase in alveolar bone loss in arthritic mice (pooled data from all mice,
means  SEM, nZ 14) compared with control (Ctrl) mice, analyzed by t-test. *P < 0.05. C: Representative photographs of the maxillae, showing evidence of
alveolar bone loss (arrows).
MC3 Controls Bone Losswith WT mice.18 We then studied if osteoclast numbers
were also different in the maxillae of the two genotypes by
quantifying the Trapþ cells in the cervical area of the ﬁrst
molar of the left lower maxillae (n Z 4 mice). Although
basal levels (1.5 months old) were different, we quantiﬁed a
40% increase in Trapþ cells in older mice in Mc3r/ but
not in WT mice, where values remained stable (Figure 6A).Figure 3 Effect of dexamethasone, DTrp, and ECT in arthritis and alveolar bone
on days 0 and 2) and monitored by daily recording the clinical score (A), paw vo
disease incidence (D). E: MPO activity was measured in the left hemimaxillae at d
and correlated with clinical score recorded that day. Drugs were administered i.p.
mouse; and vehicle PBS (Veh). Nonarthritic mice were included as controls (Ctrl).
by two-way analysis of variance, followed by a Bonferroni multiple-comparison te
comparison test (E), and Pearson correlation test (F). *P < 0.05.
The American Journal of Pathology - ajp.amjpathol.orgWe also observed a signiﬁcant increase in the number of
neutrophils in the junctional epithelium of Mc3r/ mice
compared with WT mice (Figure 6B). However, no differ-
ences were found in the rest of epithelial and connective
tissue, suggesting that neutrophils might not be playing a
crucial role in the alveolar bone loss, as measured in our
experimental conditions.loss. Arthritis was induced using the 100 þ 100 protocol (100 mL of serum
lume (B), severity (number of paws reaching the maximum score) (C), and
ay 8. F: Alveolar bone loss was analyzed in the right hemimaxillae at day 8
once daily: Dex, 10 mg per mouse; DTrp, 20 mg per mouse; ECT, 30 ng per
Data are the means  SEM of ﬁve to six mice per group. Data were analyzed
st (AeC), one-way analysis of variance, followed by a Bonferroni multiple-
2337
Figure 4 Arthritis and alveolar bone loss in MC3-deﬁcient mice.
Arthritis was induced in C57BL/6J WT mice (black) and melanocortin re-
ceptor 3edeﬁcient mice (Mc3r/) (white) using the 100 þ 100 protocol
(100 mL of serum on days 0 and 2). Disease was monitored by daily
recording of the clinical score (A), paw volume (B), and disease severity
(number of paws reaching the maximum score) (C). Alveolar bone loss was
analyzed in the right hemimaxillae on the last day of the experiment (day
8). Data are the means  SEM of ﬁve mice per group. Statistical analyses
were performed by two-way analysis of variance, followed by a Bonferroni
multiple-comparison test (AeC), and one-way analysis of variance, fol-
lowed by a Newman-Keuls multiple-comparison test versus WT-control (Ctrl;
D). *P < 0.05.
Figure 5 Impact of aging on alveolar bone loss in MC3-deﬁcient mice.
Alveolar bone loss was evaluated in the right hemimaxillae in mice from
different ages (1.5, 3.5, and 4.5 months old) in both C57BL/6J WT mice
(white circles) and melanocortin receptor 3edeﬁcient mice (Mc3r/)
(black circles). Data are the means  SEM of 6 to 17 mice. Data were
analyzed by two-way analysis of variance, followed by a Bonferroni
multiple-comparison test. *P < 0.05 versus 1.5 months; yP < 0.05 for WT
versus Mc3r/.
Montero-Melendez et alDiscussion
There is clinical evidence that periodontal disease is asso-
ciated with RA, although it is unclear whether the link is
causal or casual. Bone resorption in the maxillae (associated
with a high degree of immune cell inﬁltration) is reminiscent
of the RA joint, where many blood-borne cells can be found
in the exudate during the active phases of the disease. To
gain information on pathogenesis to subsequently inform on
therapeutic opportunities, it is important to develop animal
models in which disease development could be monitored at
the two sites in parallel.
The recent appreciation that mice subjected to the gold
standard model of RA, collagen-induced arthritis, develop
alveolar bone loss that parallels ankle joint damage,25 which
represents an important conceptual and experimental
advance. Park et al25 reported severe periodontal bone
damage 16 weeks after induction of arthritis using type II
collagen: this was associated with increased osteoclastic
activity and impaired repair ability due to reduced bone
formation by osteoblasts. Herein, we used the K/BxN serum
model of inﬂammatory arthritis, an aggressive model that
mimics the active phases of RA; also, it is much faster in its
onset. Injection of the serum rich in antieglucose-6-phos-
phate isomerase immunoglobulins ﬁxes complement onto2338cartilage with initiation of an inﬂammatory reaction, highly
reliant on cytokines and eicosanoids.27,29 Herein, we ﬁrst
determined whether this rapid model (approximately 7 to 8
days versus >30 days for the collagen-induced arthritis)
also led to periodontal disease. Thus, administration of the
arthritogenic serum along three different protocols induced
evident joint inﬂammation, with more consistent and
reproducible data with the 100 þ 100 mL protocol and mild
inﬂammation when using the 50 þ 50 mL protocol. A good
association was observed between serum dosage and pro-
tocol of administration, which resulted in distinct severity of
arthritis, and the corresponding degree of alveolar bone loss
measured in maxillae. Collectively, these data, coupled to
the two recent studies,24,25 indicate that experimental pol-
yarthritis in rodents is associated with periodontal disease
features.
The melanocortin receptor agonist ACTH is an anti-
arthritic drug indicated for the treatment of acute inﬂamma-
tory episodes of gout35 and RA, as shown by the seminal
work of Hench36 of the Mayo Clinic (Rochester, MN).37 The
equally old observations of Gutman and Yu6 have been
repeated in more rigorous clinical studies, conﬁrming ACTH
efﬁcacy in human gouty arthritis.38e40 All these studies
indicate that ACTH is effective and safe for the treatment of
acute gout and presents as a good alternative in patients with
comorbidities, in whom steroids and colchicine are not rec-
ommended. Why is ACTH so effective in arthritides? Ritter
et al40 indicated the possible existence of mechanisms aside
from adrenal stimulation and glucocorticoid release, inciting
us to identify peripheral modulation of MC3 as an important
contributor of the anti-inﬂammatory actions of the peptide.8
However, ACTH is a pan-MC receptor agonist. Herein, we
used peptide DTrp, which, although not totally selective in
in vitro expression cell systems, retains functional selectivity
in the mouse, as demonstrated by its lack of efﬁcacy in
Mc3r/ animals. More important, DTrp displays anti-
arthritic effects in the K/BxN animal model of arthritis.18,19,41ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Analysis of osteoclasts and neutro-
phils in gingival tissues. The left hemimaxillae
were used for histological evaluation of osteoclast
activity by Trap staining and neutrophil inﬁltra-
tion. A: The number of osteoclasts on the cervical
area of the ﬁrst molar. Representative images of
Trapþ cells (arrows). B: Sections were stained for
neutrophil elastase as a marker of neutrophils.
Representative images of 1.5-month-old mice.
Arrows designate neutrophils. Data are the
means  SEM of two to four mice. Data were
analyzed by one-way analysis of variance, followed
by a Bonferroni multiple-comparison test.
*P < 0.05.
MC3 Controls Bone LossThe pharmacological experiments suggested that MC-
based therapy may yield a unique opportunity. Although the
glucocorticoid Dex afforded the expected therapeutic effect
on the arthritic joint,18 measured in terms of score, swelling,
disease severity, and MPO activity, it did not affecteand
rather worsenedealveolar bone loss. This effect can be
chieﬂy due to the osteoclast activating property of gluco-
corticoids.42 Calcitonin, on the other hand, was selected
because it represented an opposite therapeutic effect, with
little modulation of inﬂammatory arthritis,43 yet its daily
delivery to mice from day 2 signiﬁcantly protected from
alveolar bone loss associated with this model of experi-
mental arthritis. This was predicted in view of the potent
action of calcitonin in stopping bone resorption,44 being
able to override the activating effect of glucocorticoids.43
DTrp revealed unique properties because it was able to
inhibit arthritis, albeit to an intermediate level between Dex
and calcitonin, and attenuated bone loss associated with
periodontal disease. In more detail, the DTrp group showed
a positive high correlation between clinical score and bone
loss (ie, reduced bone loss associated with the anti-arthritic
effect, r Z 0.87), and this was the exact opposite of that
calculated for Dex-treated mice (rZ 0.87). This ﬁnding is
of relevance because prolonged steroid therapy is associated
with bone density loss, osteoporosis, and fractures. These
results indicate that MC receptor agonists, possibly better if
selective for MC3, represent a novel class of anti-arthritic
therapeutics able to target joint disease without aggra-
vating unwanted effects on distant organs and tissues. This
notion is further substantiated by a recent study in which the
beneﬁcial effect of melanocortin treatment on jointThe American Journal of Pathology - ajp.amjpathol.orginﬂammation and against systemic muscle wasting
(cachexia) was demonstrated.21
The bone-protective effect of DTrp is likely due a direct
osteoclast effect that is additive to modulation of local
inﬂammation, as shown by the MPO activity measurements
in maxillae samples. In agreement with these pharmacolog-
ical data, we have reported a higher degree of osteoclasto-
genesis in Mc3r/ mice, measured both in vivo in arthritic
joints and in vitro, using bone marrowederived osteoclasts.18
Furthermore, in WT osteoclasts, application of DTrp reduced
cell activation and resorptive activity. In these experiments,
Mc3r/ mice did not present more pronounced arthritis, at
variance from what we reported previously,18 likely due to
differences in protocol and animal age. By the same token,
this new result allows us to separate periodontal bone loss
and joint arthritis, indicating that the former occurs inde-
pendently from modulation of the latter. Collectively, these
data prompt us to identify MC3 as a modulatory receptor on
osteoclast differentiation and activation.
The use of genetically engineered mice can shed new in-
sights into the biological functions of genes of interest. The
involvement of MC3 in bone metabolism emerges from
pharmacological evidence or from the use of Mc3r/ in set-
tings of experimental pathology. But, if MC3 plays an
important nonredundant role in bone physiology, then its
absence might produce a phenotype in healthy mice. Indeed,
these mice present decreased linear growth and femur length,
as well as reduced bone mineral density.45,46 To this end, we
monitored the degree of bone erosion in themaxillae ofmice at
different ages, comparing WT with Mc3r/ animals. These
experiments conﬁrmed a higher susceptibility to alveolar bone2339
Montero-Melendez et alloss in the transgenic mice lacking the MC3 receptor, with
presence of signiﬁcant bone loss as early as 14 weeks of age,
whereas WT mice displayed similar degrees of damage at 18
weeks. Thus, endogenous MC3, possibly activated by circu-
lating ACTH or aMSH, exerts a tonic inhibitory role on bone
metabolism in the maxillae; hence, in its absence, there is a
higher susceptibility to bone loss, hence disease. Although
congruent with the data previously presented, this hypothesis
requires corroboration by future studies. With aging,Mc3r/
mice become obese, an effect evident at 12 weeks of age.47
Because it is reported that obese mice have a different
microbiota compared with lean animals,48 one could not
exclude that a different microbiota predisposes to higher
susceptibility to periodontal disease. Again, focused and
systematic analyses on the periodontal compartment of
MC3-deﬁcient mice can shed light onto this novel biology of
the MC system we have unveiled herein.
In summary, we describe a novel experimental associa-
tion between periodontal disease and inﬂammatory arthritis
with two distinct outcomes: ﬁrst, the modulatory function of
MC3 on periodontal status in health and disease; second, the
distinct pharmacology of DTrp compared with other anti-
arthritic or bone-protective compounds, suggesting the
potential development of a new genus of anti-arthritic
therapeutics, centered on MC3 activation and able to spare
or correct alveolar bone damage.
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